



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/528,727	12/05/2005	Farid Vaghefi	P-26,238A USA	4206	
23307	7590	08/26/2008	EXAMINER		
SYNNESTVEDT & LECHNER, LLP			LEWIS, AMY A		
1101 MARKET STREET		ART UNIT		PAPER NUMBER	
SUITE 2600		1614			
PHILADELPHIA, PA 19107-2950		MAIL DATE		DELIVERY MODE	
		08/26/2008		PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/528,727	<b>Applicant(s)</b> VAGHEFI ET AL.
	<b>Examiner</b> Amy A. Lewis	<b>Art Unit</b> 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### **Status**

1) Responsive to communication(s) filed on 05 June 2008.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### **Disposition of Claims**

4) Claim(s) 1-11 and 24 is/are pending in the application.

4a) Of the above claim(s) 12-23 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1-11 and 24 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### **Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### **Priority under 35 U.S.C. § 119**

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### **Attachment(s)**

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/06/08)  
Paper No(s)/Mail Date 1/27/06

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_

5) Notice of Informal Patent Application

6) Other: \_\_\_\_\_

**DETAILED ACTION**

***Election/Restrictions***

Applicant's election **with traverse** of Group I (claims 1-11 and 24), and the species oxycodone in the reply filed on 6/5/2008 is acknowledged. The traversal is on the ground(s) that the invention does not depend on the pharmacological properties of the compounds. This is not found persuasive because, as stated previously in the Requirement for Restriction under PCT Rule 13.2 and lack a special technical feature.

The requirement is still deemed proper and is therefore made FINAL.

Claims 12-23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected subject matter, there being no allowable generic or linking claim.

Claims 1-11 and 24 are examined as far as they read upon the elected species.

Please note that the amended claims, filed on 6/5/2008, list an Application No. of 11/251465. However the Attorney docket Number for the claims is the same as for Application No. 10/528727. As the claims are the same as those listed earlier in 10/528727, the Attorney docket Number is being used to verify that the 6/5/2008 claims set does in fact belong to 10/528727.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless —

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-11 and 24 are rejected under 35 U.S.C. 102(b) as being anticipated by U.S.

Patent No. 6228863 (to Palermo et al.).

Palermo et al. teach a controlled release formulation of opioid analgesic, including oxycodone as a preferred embodiment, which has a reduced abuse potential. (See: abstract; col. 4 lines 38- col. 5 line 10; col. 14 lines 33-68). The reference teaches that the controlled release formulation can be a multiparticulate formulation which includes a sustained release carrier which is incorporated into a matrix and is applied as a sustained release coating (col. 14, lines 33-41). The reference also describes plasticizers to be used in the coating which are water insoluble (col. 17, lines 24-41).

Regarding the limitations of claims 4 and 5 regarding pH and erosion in the presence of bile salts and lipase (both known to be part of the stomach and GI-tract environment), Palermo et al. discuss the relationship of pH conditions on the properties of the formulation (col. 15, lines 15-58):

The dosage forms of the present invention may optionally be coated with one or more materials suitable for the regulation of release or for the protection of the formulation. In one embodiment, coatings are provided to permit either pH-dependent or pH-independent release, e.g., when exposed to gastrointestinal fluid. A pH-dependent coating serves to release the opioid in desired areas of the gastro-intestinal (GI) tract, e.g., the stomach or small intestine, such that an absorption profile is provided which is capable of providing at least about eight hours and preferably about twelve hours to up to about twenty-four hours of analgesia to a patient. When a pH-independent coating is desired, the coating is designed to achieve optimal release regardless of pH-changes in the environmental fluid, e.g., the GI tract. It is also possible to formulate compositions which release a portion of the dose in one desired area of the GI tract, e.g., the stomach, and release the remainder of the dose in another area of the GI tract, e.g., the small intestine.

Formulations according to the invention that utilize pH-dependent coatings to obtain formulations may also impart a repeat-action effect whereby unprotected drug is coated over the enteric coat and is released in the stomach, while the remainder, being protected by the enteric coating, is released further down the gastrointestinal tract.

Coatings which are pH-dependent may be used in accordance with the present invention...

Claim 8 is directed to the application of “mechanical stress” to the matrix and the resulting dissolution of the “active [ingredient] in said composition”. As the specification does not define what type of mechanical stress, this can include any kind of stress inflicted upon the formulation as it travels through the subject ingesting it (such as, chewing, pressure from normal peristalsis along the GI- tract), or even crushing of the formulation before it is even ingested. Therefore, the formulation of Palermo et al., having the same formulation characteristics, meets these limitations.

***Conclusion***

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy A. Lewis whose telephone number is 571-272-9032. The examiner can normally be reached on Monday-Friday 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amy A Lewis/  
Examiner, Art Unit 1614

Application/Control Number: 10/528,727  
Art Unit: 1614

Page 5

/Ardin Marschel/  
Supervisory Patent Examiner, Art Unit 1614